Sample Business Contracts
Joinder Agreement - Valeant Pharmaceuticals International Inc. and Goldman Sachs Lending Partners LLC
EXECUTION VERSION
JOINDER AGREEMENT
This Joinder Agreement is dated as of February 6, 2014 (this "Agreement"), by and among each of the financial institutions set forth on Schedule A annexed hereto (each a "New Term Loan Lender" and collectively the "New Term Loan Lenders"), Valeant Pharmaceuticals International, Inc., a corporation continued under the laws of the Province of British Columbia ("Borrower"), the undersigned subsidiaries of Borrower and Goldman Sachs Lending Partners LLC ("GSLP"), as Administrative Agent and Collateral Agent.
RECITALS:
WHEREAS, reference is hereby made to the Third Amended and Restated Credit and Guaranty Agreement, dated as of February 13, 2012, as amended by Amendment No. 1, dated as of March 6, 2012, by Amendment No. 2, dated as of September 10, 2012, by Amendment No. 3, dated as of January 24, 2013, by Amendment No. 4, dated as of February 21, 2013, by Amendment No. 5, dated as of June 6, 2013, by Amendment No. 6, dated as of June 26, 2013, by Amendment No. 7, dated as of September 17, 2013, by Amendment No. 8, dated as of December 20, 2013 ("Amendment No. 8"), as further supplemented by the Joinder Agreement, dated as of June 14, 2012, by the Joinder Agreement, dated as of July 9, 2012, by the Joinder Agreement, dated as of September 11, 2012, by the Joinder Agreement dated as of October 2, 2012, by the Joinder Agreement, dated as of December 11, 2012 and by the Joinder Agreements, each dated as of August 5, 2013 (as it may be amended, restated, replaced, supplemented or otherwise modified from time to time, the "Credit Agreement"; the terms defined therein and not otherwise defined herein being used herein as therein defined), among Borrower, certain Subsidiaries of Borrower, as Guarantors, the Lenders party thereto from time to time, GSLP, J.P. Morgan Securities LLC and Morgan Stanley Senior Funding, Inc. ("Morgan Stanley"), as Joint Lead Arrangers and Joint Bookrunners, JPMorgan Chase Bank, N.A. ("JPMorgan") and Morgan Stanley, as Co-Syndication Agents, JPMorgan, as Issuing Bank, GSLP, as Administrative Agent and Collateral Agent, and the other Agents party thereto;
WHEREAS, subject to the terms and conditions of the Credit Agreement, Borrower may obtain New Revolving Loan Commitments and/or New Term Loan Commitments by entering into one or more Joinder Agreements with the New Term Loan Lenders;
WHEREAS, pursuant to Section 2.25 of the Credit Agreement, the Credit Agreement may, without the consent of any other Lenders, be amended as may be necessary or appropriate, in the opinion of the Administrative Agent, to give effect to the provisions of Section 2.25 of the Credit Agreement; and
WHEREAS, the Borrower may, in its sole discretion, use the proceeds of the Additional Series A-3 Tranche A Term Loans (as defined below) for any purpose not prohibited by the Credit Agreement, including repayment of outstanding Indebtedness of the Borrower.
NOW, THEREFORE, in consideration of the premises and agreements, provisions and covenants herein contained, the parties hereto agree as follows:
Each New Term Loan Lender (i) confirms that it has received a copy of the Credit Agreement and the other Credit Documents, together with copies of the financial statements referred to therein and such other documents and information as it has deemed appropriate to make its own credit analysis and decision to enter into this Agreement; (ii) agrees that it will, independently and without reliance
upon the Administrative Agent or any other Lender or Agent and based on such documents and information as it shall deem appropriate at the time, continue to make its own credit decisions in taking or not taking action under the Credit Agreement; (iii) appoints and authorizes Administrative Agent and each other Agent to take such action as agent on its behalf and to exercise such powers under the Credit Agreement and the other Credit Documents as are delegated to Administrative Agent or such other Agent, as the case may be, by the terms thereof, together with such powers as are reasonably incidental thereto; and (iv) agrees that it will perform in accordance with their terms all of the obligations which by the terms of the Credit Agreement are required to be performed by it as a Lender.
Each New Term Loan Lender hereby commits to provide its respective New Term Loan Commitment (each an "Additional Series A-3 Tranche A Term Loan Commitment") as set forth on Schedule A annexed hereto, on the terms and subject to the conditions set forth below:
| 1. | Additional Series A-3 Tranche A Term Loan Commitments. The terms and provisions of the New Term Loans made pursuant to this Agreement (the "Additional Series A-3 Tranche A Term Loans" and each an "Additional Series A-3 Tranche A Term Loan") shall be identical to, and constitute, Series A-3 Tranche A Term Loans for all purposes under the Credit Agreement. The Additional Series A-3 Tranche A Term Loan Commitments and Additional Series A-3 Tranche A Term Loans made pursuant thereto shall be subject to the provisions of the Credit Agreement and the other Credit Documents, and shall constitute "Tranche A Term Loan Exposure" and "Tranche A Term Loans", respectively, thereunder. |
| 2. | Closing Fee. Borrower agrees to pay on the Additional Series A-3 Tranche A Term Loan Funding Date (as defined below) to Administrative Agent, for the account of each New Term Loan Lender party to this Agreement, as fee compensation for the commitment of such New Term Loan Lender's Additional Series A-3 Tranche A Loan Commitments, a closing fee in an amount equal to 0.25% of the aggregate principal amount of such New Term Loan Lender's allocated Additional Series A-3 Tranche A Term Loan Commitments which are actually funded on the Additional Series A-3 Tranche A Term Loan Funding Date. |
| 3. | Proposed Borrowing. In accordance with Section 2.25 of the Credit Agreement, Borrower has previously delivered to Administrative Agent an executed Funding Notice for Additional Series A-3 Tranche A Term Loans, requesting a proposed borrowing in the principal amount of up to $225,560,593.40 (the "Proposed Borrowing") on the date hereof (the "Additional Series A-3 Tranche A Term Loan Funding Date"). Each New Term Loan Lender shall make its Additional Series A-3 Tranche A Term Loan available to Administrative Agent not later than 11:00 a.m. (New York City time) on the date hereof, by wire transfer of same day funds in Dollars at the Principal Office designated by Administrative Agent. Promptly upon receipt thereof, Administrative Agent shall make the proceeds of the Additional Series A-3 Tranche A Term Loan available to Borrower on the date hereof by causing an amount of same day funds in Dollars equal to the proceeds of all such loans received by Administrative Agent from New Term Loan Lenders to be credited to the account of Borrower, at the Principal Office designated by Administrative Agent or to such other account as may be designated in writing to Administrative Agent by Borrower. |
| 4. | New Lenders. Each New Term Loan Lender (other than any New Term Loan Lender that, immediately prior to the execution of this Agreement, is a "Lender" under the Credit Agreement) acknowledges and agrees that upon its execution of this Agreement its Additional Series A-3 Tranche A Term Loan Commitments shall be effective and that such New Term Loan Lender shall become a "Lender" under, and for all purposes of, the Credit Agreement and the other Credit Documents, and shall be subject to and bound by the terms thereof, and shall perform all the obligations of and shall have all rights of a Lender thereunder. |
-2-
| 5. | Credit Agreement Governs. Additional Series A-3 Tranche A Term Loans shall be subject to the provisions of the Credit Agreement and the other Credit Documents, except as set forth in this Agreement, and shall constitute Tranche A Term Loans thereunder. |
| 6. | Borrower's Certifications. By its execution of this Agreement, the undersigned officer, to the best of his or her knowledge, and Borrower hereby certify that: |
| i. | The representations and warranties contained in the Credit Agreement and the other Credit Documents are true and correct in all material respects on and as of the date hereof to the same extent as though made on and as of the date hereof, except to the extent such representations and warranties specifically relate to an earlier date, in which case such representations and warranties were true and correct in all material respects on and as of such earlier date; |
| ii. | No event has occurred and is continuing or would result from the consummation of the Proposed Borrowing contemplated hereby that would constitute a Default or an Event of Default; and |
| iii. | Borrower has performed in all material respects all agreements and satisfied all conditions which the Credit Agreement provides shall be performed or satisfied by it on or before the date hereof in connection with the Proposed Borrowing. |
| 7. | Borrower Covenants. By its execution of this Agreement, Borrower hereby covenants that: |
| i. | Borrower shall deliver or cause to be delivered, on or before the Additional Series A-3 Tranche A Term Loan Funding Date, the following legal opinions and documents: originally executed copies of the favorable written opinions of (a) Skadden, Arps, Slate, Meagher & Flom LLP, U.S. counsel to the Credit Parties, (b) Chancery Chambers, special Barbados counsel to the Credit Parties, (c) Norton Rose Fulbright Canada LLP, special Canadian counsel to the Credit Parties, (d) Baker & McKenzie, special Luxembourg counsel to the Credit Parties, (e) Conyers Dill & Pearman Limited, special Bermuda counsel to the Credit Parties, (f) Arthur Cox, special Ireland counsel to the Credit Parties, (g) Baker & McKenzie, special Switzerland counsel to the Credit Parties, (h) Venable LLP, special Maryland counsel to the Credit Parties, (i) Souza, Cescon, Barrieu & Flesch Advogados, special Brazil counsel to the Credit Parties, (j) Squire Sanders Święcicki Krześniak sp.k., special Poland counsel to the Credit Parties and (k) Tark Grunte Sutkiene, special Lithuania counsel to the Credit Parties, together with all other legal opinions and other documents reasonably requested by Administrative Agent in connection with this Agreement. |
| 8. | Eligible Assignee. By its execution of this Agreement, each New Term Loan Lender (other than any New Term Loan Lender that, immediately prior to the execution of this Agreement, is a "Lender" under the Credit Agreement) represents and warrants that it is an Eligible Assignee. |
| 9. | Notice. For purposes of the Credit Agreement, the initial notice address of each New Term Loan Lender shall be as set forth below its signature below. |
| 10. | Non-U.S. Lenders. For each New Term Loan Lender that is a Non-U.S. Lender, delivered herewith to Administrative Agent are such forms, certificates or other evidence with respect to United States federal income tax withholding matters as such New Term Loan Lender may be required to deliver to Administrative Agent pursuant to subsection 2.20(d) of the Credit Agreement. |
-3-
| 11. | Recordation of the New Loans. Upon execution and delivery hereof, Administrative Agent will record in the Register the Additional Series A-3 Tranche A Term Loans made by New Term Loan Lenders pursuant hereto as being of the same Class as the Series A-3 Tranche A Term Loans. |
| 12. | Reaffirmation. |
| i. | Each Credit Party hereby expressly acknowledges the terms of this Agreement and reaffirms, as of the date hereof, the covenants and agreements contained in each Credit Document to which it is a party, including, in each case, such covenants and agreements as in effect immediately after giving effect to this Agreement and the transactions contemplated hereby. |
| ii. | Each Credit Party, by its signature below, hereby affirms and confirms (a) its obligations under each of the Credit Documents to which it is a party, and (b) the pledge of and/or grant of a security interest or hypothec in its assets as Collateral to secure such Obligations, all as provided in the Collateral Documents as originally executed, and acknowledges and agrees that such guarantee, pledge and/or grant continue in full force and effect in respect of, and to secure, such Obligations under the Credit Agreement and the other Credit Documents. |
| iii. | Each Credit Party acknowledges and agrees that each of the Credit Documents in existence as of the date hereof shall be henceforth read and construed in accordance with and so as to give full force and effect to the ratifications, confirmations, acknowledgements and agreements made herein. |
| 13. | Amendment, Modification and Waiver. This Agreement may not be amended, modified or waived except by an instrument or instruments in writing signed and delivered on behalf of each of the parties hereto. |
| 14. | Entire Agreement. This Agreement, the Credit Agreement, the other Credit Documents and the letter agreement dated as of February 4, 2014 between the New Term Loan Lenders, the Borrower and GSLP as Administrative Agent and Collateral Agent constitute the entire agreement among the parties with respect to the subject matter hereof and thereof and supersede all other prior agreements and understandings, both written and verbal, among the parties or any of them with respect to the subject matter hereof. It is understood and agreed that each reference in each Credit Document to the Credit Agreement, whether direct or indirect, shall hereafter be deemed to be a reference to the Credit Agreement as amended and supplemented hereby and that this Agreement is a Credit Document. |
| 15. | GOVERNING LAW. THIS AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK. |
| 16. | Severability. Any term or provision of this Agreement which is invalid or unenforceable in any jurisdiction shall, as to that jurisdiction, be ineffective to the extent of such invalidity or unenforceability without rendering invalid or unenforceable the remaining terms and provisions of this Agreement or affecting the validity or enforceability of any of the terms or provisions of this Agreement in any other jurisdiction. If any provision of this Agreement is so broad as to be unenforceable, the provision shall be interpreted to be only so broad as would be enforceable. |
-4-
| 17. | Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed to be an original, but all of which shall constitute one and the same agreement. |
[Remainder of page intentionally left blank]
-5-
IN WITNESS WHEREOF, each of the undersigned has caused its duly authorized officer to execute and deliver this Agreement as of the date first written above.
| BARCLAYS BANK PLC as a "New Term | ||
| Loan Lender" | ||
| By: |
/s/ Naom Azachi |
|
| Name: | Naom Azachi | |
| Title: | Vice President | |
| Notice Address: | ||
| 745 7th Avenue | ||
| New York, NY 10019 | ||
| Attention: | Mathew Cybul | |
| Telephone: | 212-526-5851 | |
| Facsimile: | 212-526-5115 | |
[Signature Page to Joinder Agreement]
| CITIBANK, N.A., as a "New Term Loan | ||
| Lender" | ||
| By: |
/s/ Laura Fogarty |
|
| Name: | Laura Fogarty | |
| Title: | Vice President | |
| Notice Address: | ||
| 388 Greenwich Street, Floor 32 | ||
| New York, NY 10013 | ||
| Attention: | Laura Fogarty | |
| Telephone: | (212) 816-2197 | |
| Facsimile: | (646) 862-8137 | |
[Signature Page to Joinder Agreement]
| MORGAN STANLEY SENIOR FUNDING | ||
| INC., as a "New Term Loan Lender" | ||
| By: |
/s/ Alice Lee |
|
| Name: | Alice Lee | |
| Title: | Authorized Signatory | |
| Notice Address: | ||
| Morgan Stanley Loan Servicing | ||
| 1300 Thames Street Wharf, 4th Floor | ||
| Baltimore, MD 21231 | ||
| 443-627-4355 | ||
| 718-233-2140 | ||
| [email protected] | ||
[Signature Page to Joinder Agreement]
| SUNTRUST BANK, as a "New Term Loan | ||
| Lender" | ||
| By: |
/s/ Katherine Bass |
|
| Name: | Katherine Bass | |
| Title: | Director | |
| Notice Address: | ||
| 3333 Peachtree Road, NE | ||
| 7th Floor | ||
| Atlanta, GA 30326 | ||
| Attention: Katherine Bass | ||
| Telephone: 404-439-7602 | ||
| Facsimile: 404-439-7600 | ||
[Signature Page to Joinder Agreement]
| DBS BANK LTD., LOS ANGELES | ||
| AGENCY, as a "New Term Loan Lender" | ||
| By: |
/s/ James McWalters |
|
| Name: | James McWalters | |
| Title: | General Manager | |
| Notice Address: | ||
| 725 South Figueroa Street Suite 2000 | ||
| Los Angeles, CA 90017 | ||
| Attention: | General Manager | |
| Telephone: | 213-627-0222 | |
| Facsimile: | 213-627-0228 | |
[Signature Page to Joinder Agreement]
IN WITNESS WHEREOF, each of the undersigned has caused its duly authorized officer to execute and deliver this Amendment No. 8 as of the date first written above.
| VALEANT PHARMACEUTICALS | ||||
| INTERNATIONAL, INC. | ||||
| as Borrower | ||||
| By: |
/s/ Linda LaGorga |
|||
| Name: | Linda LaGorga | |||
| Title: | Senior Vice President and Treasurer | |||
| VALEANT PHARMACEUTICALS | ||||
| INTERNATIONAL | ||||
| as Guarantor | ||||
| By: |
/s/ Howard B. Schiller |
|||
| Name: | Howard B. Schiller | |||
| Title: | Executive Vice President and Chief | |||
| Financial Officer | ||||
| BAUSCH & LOMB INCORPORATED | ||||
| as Guarantor | ||||
| By: |
/s/ Howard B. Schiller |
|||
| Name: | Howard B. Schiller | |||
| Title: | Executive Vice President and Chief | |||
| Financial Officer | ||||
| BAUSCH & LOMB HOLDINGS | ||||
| INCORPORATED | ||||
| as Guarantor | ||||
| By: |
/s/ Linda LaGorga |
|||
| Name: | Linda LaGorga | |||
| Title: | Vice President and Treasurer | |||
[Signature Page to Joinder Agreement]
|
ATON PHARMA, INC. as Guarantor |
||||
| By: |
/s/ Howard B. Schiller |
|||
| Name: | Howard B. Schiller | |||
| Title: | Executive Vice President and Chief | |||
| Financial Officer | ||||
|
CORIA LABORATORIES, LTD. as Guarantor |
||||
| By: |
/s/ Howard B. Schiller |
|||
| Name: | Howard B. Schiller | |||
| Title: | Executive Vice President and Chief | |||
| Financial Officer | ||||
|
DOW PHARMACEUTICAL SCIENCES, INC. as Guarantor |
||||
| By: |
/s/ Howard B. Schiller |
|||
| Name: | Howard B. Schiller | |||
| Title: | Executive Vice President and Chief | |||
| Financial Officer | ||||
|
OBAGI MEDICAL PRODUCTS, INC. as Guarantor |
||||
| By: |
/s/ Linda LaGorga |
|||
| Name: | Linda LaGorga | |||
| Title: | Treasurer | |||
|
OMP, INC. as Guarantor |
||||
| By: |
/s/ Linda LaGorga |
|||
| Name: | Linda LaGorga | |||
| Title: | Treasurer | |||
[Signature Page to Joinder Agreement]
|
MEDICIS PHARMACEUTICAL CORPORATION as Guarantor |
||||
| By: |
/s/ Howard B. Schiller |
|||
| Name: | Howard B. Schiller | |||
| Title: | Executive Vice President, Chief | |||
| Financial Officer and Treasurer | ||||
|
DR. LEWINN'S PRIVATE FORMULA INTERNATIONAL, INC. as Guarantor |
||||
| By: |
/s/ Howard B. Schiller |
|||
| Name: | Howard B. Schiller | |||
| Title: | Chief Financial Officer and Treasurer | |||
|
OCEANSIDE PHARMACEUTICALS, INC. as Guarantor |
||||
| By: |
/s/ Howard B. Schiller |
|||
| Name: | Howard B. Schiller | |||
| Title: | Chief Financial Officer and Treasurer | |||
|
PRINCETON PHARMA HOLDINGS, LLC as Guarantor |
||||
| By: |
/s/ Howard B. Schiller |
|||
| Name: | Howard B. Schiller | |||
| Title: | Chief Financial Officer and Treasurer | |||
[Signature Page to Joinder Agreement]
| PRIVATE FORMULA CORP. | ||||
| as Guarantor | ||||
| By: |
/s/ Howard B. Schiller |
|||
| Name: | Howard B. Schiller | |||
| Title: | Chief Financial Officer and Treasurer | |||
|
RENAUD SKIN CARE LABORATORIES, INC. as Guarantor |
||||
| By: |
/s/ Howard B. Schiller |
|||
| Name: | Howard B. Schiller | |||
| Title: | Chief Financial Officer and Treasurer | |||
| VALEANT BIOMEDICALS, INC. | ||||
| as Guarantor | ||||
| By: |
/s/ Howard B. Schiller |
|||
| Name: | Howard B. Schiller | |||
| Title: | Chief Financial Officer and Treasurer | |||
|
VALEANT PHARMACEUTICALS NORTH AMERICA LLC as Guarantor |
||||
| By: |
/s/ Howard B. Schiller |
|||
| Name: | Howard B. Schiller | |||
| Title: | Executive Vice President and Chief | |||
| Financial Officer | ||||
|
BIOVAIL AMERICAS CORP. as Guarantor |
||||
| By: |
/s/ Howard B. Schiller |
|||
| Name: | Howard B. Schiller | |||
| Title: | Chief Financial Officer and Treasurer | |||
[Signature Page to Joinder Agreement]
|
ORAPHARMA, INC. as Guarantor |
||||
| By: |
/s/ Howard B. Schiller |
|||
| Name: | Howard B. Schiller | |||
| Title: | Executive Vice President, Chief | |||
| Financial Officer and Treasurer | ||||
|
ORAPHARMA TOPCO HOLDINGS, INC. as Guarantor |
||||
| By: |
/s/ Howard B. Schiller |
|||
| Name: | Howard B. Schiller | |||
| Title: | Executive Vice President, Chief | |||
| Financial Officer and Treasurer | ||||
|
PRESTWICK PHARMACEUTICALS, INC. as Guarantor |
||||
| By: |
/s/ Howard B. Schiller |
|||
| Name: | Howard B. Schiller | |||
| Title: | Chief Financial Officer and Treasurer | |||
|
IOLAB CORPORATION as Guarantor |
||||
| By: |
/s/ Linda LaGorga |
|||
| Name: | Linda LaGorga | |||
| Title: | Treasurer | |||
|
TECHNOLAS PERFECT VISION, INC. as Guarantor |
||||
| By: |
/s/ Linda LaGorga |
|||
| Name: | Linda LaGorga | |||
| Title: | Vice President and Treasurer | |||
|
BAUSCH & LOMB PHARMA HOLDINGS CORP. as Guarantor |
||||
| By: |
/s/ Linda LaGorga |
|||
| Name: | Linda LaGorga | |||
| Title: | Treasurer | |||
[Signature Page to Joinder Agreement]
|
BAUSCH & LOMB CHINA, INC. as Guarantor |
||||
| By: |
/s/ Linda LaGorga |
|||
| Name: | Linda LaGorga | |||
| Title: | Vice President and Treasurer | |||
|
BAUSCH & LOMB SOUTH ASIA, INC. as Guarantor |
||||
| By: |
/s/ Linda LaGorga |
|||
| Name: | Linda LaGorga | |||
| Title: | Vice President and Treasurer | |||
|
BAUSCH & LOMB TECHNOLOGY CORPORATION as Guarantor |
||||
| By: |
/s/ Linda LaGorga |
|||
| Name: | Linda LaGorga | |||
| Title: | Treasurer | |||
|
RHC HOLDINGS, INC. as Guarantor |
||||
| By: |
/s/ Linda LaGorga |
|||
| Name: | Linda LaGorga | |||
| Title: | Treasurer | |||
|
SIGHT SAVERS, INC. as Guarantor |
||||
| By: |
/s/ Linda LaGorga |
|||
| Name: | Linda LaGorga | |||
| Title: | Vice President and Treasurer | |||
[Signature Page to Joinder Agreement]
| BAUSCH & LOMB INTERNATIONAL INC. | ||||
| as Guarantor | ||||
| By: |
/s/ Linda LaGorga |
|||
| Name: | Linda LaGorga | |||
| Title: | Vice President and Treasurer | |||
| BAUSCH & LOMB REALTY CORPORATION | ||||
| as Guarantor | ||||
| By: |
/s/ Linda LaGorga |
|||
| Name: | Linda LaGorga | |||
| Title: | Vice President and Treasurer | |||
[Signature Page to Joinder Agreement]
| ISTA PHARMACEUTICALS, LLC | ||||
| as Guarantor | ||||
| By: |
/s/ Linda LaGorga |
|||
| Name: | Linda LaGorga | |||
| Title: | Vice President and Treasurer | |||
| VRX HOLDCO INC. | ||||
| as Guarantor | ||||
| By: |
/s/ Linda LaGorga |
|||
| Name: | Linda LaGorga | |||
| Title: | Chief Financial Officer and Treasurer | |||
[Signature Page to Joinder Agreement]
| VALEANT INTERNATIONAL BERMUDA | ||||
| as Guarantor | ||||
| By: |
/s/ Peter J. McCurdy |
|||
| Name: | Peter J. McCurdy | |||
| Title: | President and Assistant Secretary | |||
| VALEANT PHARMACEUTICALS NOMINEE BERMUDA | ||||
| as Guarantor | ||||
| By: |
/s/ Peter J. McCurdy |
|||
| Name: | Peter J. McCurdy | |||
| Title: | President and Assistant Secretary | |||
[Signature Page to Joinder Agreement]
| HYTHE PROPERTY INCORPORATED | ||||
| as Guarantor | ||||
| By: |
/s/ Mauricio Zavala |
|||
| Name: | Mauricio Zavala | |||
| Title: | Assistant Secretary | |||
[Signature Page to Joinder Agreement]
| VALEANT CANADA GP LIMITED | ||||
| as Guarantor | ||||
| By: |
/s/ Robert R. Chai-Onn |
|||
| Name: | Robert R. Chai-Onn | |||
| Title: | Executive Vice President and General Counsel | |||
|
VALEANT CANADA LP by its sole general partner, VALEANT CANADA GP LIMITED as Guarantor |
||||
| By: |
/s/ Robert R. Chai-Onn |
|||
| Name: | Robert R. Chai-Onn | |||
| Title: | Executive Vice President and General Counsel | |||
| V-BAC HOLDING CORP. | ||||
| as Guarantor | ||||
| By: |
/s/ Robert R. Chai-Onn |
|||
| Name: | Robert R. Chai-Onn | |||
| Title: | Vice President | |||
[Signature Page to Joinder Agreement]
| VALEANT PHARMACEUTICALS IRELAND | ||||
| as Guarantor | ||||
| By: |
/s/ Graham Jackson |
|||
| Name: | Graham Jackson | |||
| Title: | Director | |||
[Signature Page to Joinder Agreement]
| BIOVAIL INTERNATIONAL S.À R.L. | ||||
| as Guarantor | ||||
| By: |
/s/ Kuy Ly Ang |
|||
| Name: | Kuy Ly Ang | |||
| Title: | Manager | |||
| VALEANT PHARMACEUTICALS LUXEMBOURG S.À R.L. | ||||
| as Guarantor | ||||
| By: |
/s/ Kuy Ly Ang |
|||
| Name: | Kuy Ly Ang | |||
| Title: | Manager | |||
[Signature Page to Joinder Agreement]
| PHARMASWISS SA | ||||
| as Guarantor | ||||
| By: |
/s/ Matthias Courvoisier |
|||
| Name: | Matthias Courvoisier | |||
| Title: | Director | |||
[Signature Page to Joinder Agreement]
| Signed by | ||||
| Valeant Holdco 2 Pty Ltd (ACN 154 341 367) | ||||
|
as Guarantor in accordance with section 127 of the Corporations Act 2001 by two directors: |
||||
|
/s/ Robert R. Chai-Onn |
/s/ Howard B. Schiller |
|||
| Signature of director | Signature of director | |||
|
Robert R. Chai-Onn |
Howard B. Schiller |
|||
| Name of director (please print) | Name of director (please print) | |||
| Signed by | ||||
| Wirra Holdings Pty Limited (ACN 122 216 577) | ||||
|
as Guarantor in accordance with section 127 of the Corporations Act 2001 by two directors: |
||||
|
/s/ Robert R. Chai-Onn |
/s/ Howard B. Schiller |
|||
| Signature of director | Signature of director | |||
|
Robert R. Chai-Onn |
Howard B. Schiller |
|||
| Name of director (please print) | Name of director (please print) | |||
[Signature Page to Joinder Agreement]
| Signed by | ||||
| Wirra Operations Pty Limited (ACN 122 250 088) | ||||
|
as Guarantor in accordance with section 127 of the Corporations Act 2001 by two directors: |
||||
|
/s/ Robert R. Chai-Onn |
Howard B. Schiller |
|||
| Signature of director | Signature of director | |||
|
Robert R. Chai-Onn |
Howard B. Schiller |
|||
| Name of director (please print) | Name of director (please print) | |||
| Signed by | ||||
| iNova Pharmaceuticals (Australia) Pty Limited (ACN 000 222 408) | ||||
|
as Guarantor in accordance with section 127 of the Corporations Act 2001 by two directors: |
||||
|
/s/ Robert R. Chai-Onn |
Howard B. Schiller |
|||
| Signature of director | Signature of director | |||
|
Robert R. Chai-Onn |
Howard B. Schiller |
|||
| Name of director (please print) | Name of director (please print) | |||
| Signed by | ||||
| Wirra IP Pty Limited (ACN 122 536 350) | ||||
|
as Guarantor in accordance with section 127 of the Corporations Act 2001 by two directors: |
||||
|
/s/ Robert R. Chai-Onn |
Howard B. Schiller |
|||
| Signature of director | Signature of director | |||
|
Robert R. Chai-Onn |
Howard B. Schiller |
|||
| Name of director (please print) | Name of director (please print) | |||
[Signature Page to Joinder Agreement]
| Signed by | ||||
| iNova Sub Pty Limited (ACN 134 398 815) | ||||
|
as Guarantor in accordance with section 127 of the Corporations Act 2001 by two directors: |
||||
|
/s/ Robert R. Chai-Onn |
Howard B. Schiller |
|||
| Signature of director | Signature of director | |||
|
Robert R. Chai-Onn |
Howard B. Schiller |
|||
| Name of director (please print) | Name of director (please print) | |||
[Signature Page to Joinder Agreement]
| Signed by | ||||
| Valeant Pharmaceuticals Australasia Pty Limited (ACN 001 083 352) | ||||
|
as Guarantor in accordance with section 127 of the Corporations Act 2001 by a director and secretary/director: |
||||
|
/s/ Robert R. Chai-Onn |
/s/ Linda A. LaGorga |
|||
| Signature of director | Signature of director/secretary | |||
|
Robert R. Chai-Onn |
Linda A. LaGorga |
|||
| Name of director (please print) | Name of director/secretary (please print) | |||
| Signed by | ||||
| DermaTech Pty Limited (ACN 003 982 161) | ||||
|
as Guarantor in accordance with section 127 of the Corporations Act 2001 by a director and secretary/director: |
||||
|
/s/ Robert R. Chai-Onn |
/s/ Howard B. Schiller |
|||
| Signature of director | Signature of director/secretary | |||
|
Robert R. Chai-Onn |
Howard B. Schiller |
|||
| Name of director (please print) | Name of director/secretary (please print) | |||
[Signature Page to Joinder Agreement]
| Signed by | ||||
| Private Formula International Holdings Pty Ltd (ACN 095 450 918) | ||||
|
as Guarantor in accordance with section 127 of the Corporations Act 2001 by a director and secretary/director: |
||||
|
/s/ Robert R. Chai-Onn |
/s/ Howard B. Schiller |
|||
| Signature of director | Signature of director/secretary | |||
|
Robert R. Chai-Onn |
Howard B. Schiller |
|||
| Name of director (please print) | Name of director/secretary (please print) | |||
| Signed by | ||||
| Private Formula International Pty Ltd (ACN 095 451 442) | ||||
|
as Guarantor in accordance with section 127 of the Corporations Act 2001 by a director and secretary/director: |
||||
|
/s/ Robert R. Chai-Onn |
/s/ Howard B. Schiller |
|||
| Signature of director | Signature of director/secretary | |||
|
Robert R. Chai-Onn |
Howard B. Schiller |
|||
| Name of director (please print) | Name of director/secretary (please print) | |||
[Signature Page to Joinder Agreement]
| Signed by | ||||
| Ganehill Pty Ltd (ACN 065 261 538) | ||||
|
as Guarantor in accordance with section 127 of the Corporations Act 2001 by a director and secretary/director: |
||||
|
/s/ Robert R. Chai-Onn |
/s/ Howard B. Schiller |
|||
| Signature of director | Signature of director/secretary | |||
|
Robert R. Chai-Onn |
Howard B. Schiller |
|||
| Name of director (please print) | Name of director/secretary (please print) | |||
[Signature Page to Joinder Agreement]
| UCYCLYD PHARMA, INC. | ||||
| as Guarantor | ||||
| By: |
/s/ Howard B. Schiller |
|||
| Name: | Howard B. Schiller | |||
| Title: |
Executive Vice President, Chief Financial Officer |
|||
[Signature Page to Joinder Agreement]
| VALEANT EUROPE B.V. | ||||
| as Guarantor | ||||
| By: |
/s/ Rob Meijer |
|||
| Name: | Rob Meijer | |||
| Title: | Managing Director A | |||
[Signature Page to Joinder Agreement]
|
PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A. |
||||
| as Guarantor | ||||
| By: |
/s/ Marcin Wnukowski |
|||
| Name: | Marcin Wnukowski | |||
| Title: | Attorney-In-Fact | |||
| VALEANT SP. ZOO | ||||
| as Guarantor | ||||
| By: |
/s/ Marcin Wnukowski |
|||
| Name: | Marcin Wnukowski | |||
| Title: | Attorney-In-Fact | |||
|
VP VALEANT SP. Z.O.O.SP.J. as Guarantor |
||||
| By: |
/s/ Marcin Wnukowski |
|||
| Name: | Marcin Wnukowski | |||
| Title: | Attorney-In-Fact | |||
|
VALEANT SPOLKA Z ORGANICZONA ODPOWIEDZIALNOSCIA SP.J. |
||||
| as Guarantor | ||||
| By: |
/s/ Marcin Wnukowski |
|||
| Name: | Marcin Wnukowski | |||
| Title: | Attorney-In-Fact | |||
[Signature Page to Joinder Agreement]
| LABENNE PARTICIPACOES LTDA | ||||
| as Guarantor | ||||
| By: |
/s/ Marcelo Noll Barboza |
|||
| Name: | Marcelo Noll Barboza | |||
| Title: | Officer | |||
| By: |
/s/ Mauricio Santos da Luz |
|||
| Name: | Mauricio Santos da Luz | |||
| Title: | Officer | |||
| PROBIOTICA LABORATORIES LTDA. | ||||
| as Guarantor | ||||
| By: |
/s/ Marcelo Noll Barboza |
|||
| Name: | Marcelo Noll Barboza | |||
| Title: | Officer | |||
| By: |
/s/ Mauricio Santos da Luz |
|||
| Name: | Mauricio Santos da Luz | |||
| Title: | Officer | |||
[Signature Page to Joinder Agreement]
| AB SANITAS | ||||
| as Guarantor | ||||
| By: |
/s/ Saulius Žemaitis |
|||
| Name: | Saulius Žemaitis | |||
| Title: | General Manager | |||
[Signature Page to Joinder Agreement]
| Consented to by: | ||
| GOLDMAN SACHS LENDING PARTNERS LLC | ||
| As Administrative Agent and Collateral Agent | ||
| By: |
/s/ Elizabeth Fischer |
|
| Authorized Signatory | ||
[Signature Page to Joinder Agreement]
SCHEDULE A
TO JOINDER AGREEMENT
|
Name of Lender |
Type of Commitment |
Amount | ||||
|
BARCLAYS BANK PLC |
Additional Series A-3 Tranche A Term Loan Commitment | $ | 74,952,387.64 | |||
|
CITIBANK, N.A. |
Additional Series A-3 Tranche A Term Loan Commitment | $ | 75,000,000.00 | |||
|
MORGAN STANLEY SENIOR FUNDING, INC. |
Additional Series A-3 Tranche A Term Loan Commitment | $ | 20,770,632.32 | |||
|
SUNTRUST BANK |
Additional Series A-3 Tranche A Term Loan Commitment | $ | 36,837,573.44 | |||
|
DBS BANK LTD., LOS ANGELES AGENCY |
Additional Series A-3 Tranche A Term Loan Commitment | $ | 18,000,000.00 | |||
| |
|
|||||
| Total: $ | 225,560,593.40 | |||||
| |
|
|||||